Laurus Labs Limited
NSE: LAURUSLABS BSE: LAURUSLABS
NSE
953.65
-16.70 (-1.72%)
Prev Close
970.35
Open Price
970.9
Volume
1,545,364
Today Low / High
950.2 / 972.4
52 WK Low / High
474.05 / 972.55
Range
906 - 1,001
BSE
954.50
-15.50 (-1.60%)
Prev Close
970
Open Price
970.5
Volume
70,633
Today Low / High
950.8 / 972.6
52 WK Low / High
474.25 / 972.6
Range
907 - 1,002
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 953.65 (target range: 906 - 1,001), reflecting a change of -16.7 (-1.72103%). On the BSE, it is listed at 954.5 (target range: 907 - 1,002), showing a change of -15.5 (-1.59794%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
30 Oct
962.90
0.85%
29 Oct
964.15
-0.25%
28 Oct
941.00
1.98%
27 Oct
930.40
1.05%
24 Oct
943.00
-1.76%
23 Oct
927.40
0.75%
21 Oct
925.85
-0.21%
20 Oct
903.05
1.95%
17 Oct
872.85
3.12%
16 Oct
877.00
-0.47%
15 Oct
880.00
-0.53%
14 Oct
876.30
0.19%
13 Oct
877.45
-0.36%
10 Oct
873.00
0.43%
09 Oct
861.10
0.46%
08 Oct
863.00
-1.06%
07 Oct
865.00
-0.18%
06 Oct
866.05
-0.35%
03 Oct
872.00
-0.87%
Laurus Labs Limited Graph
Laurus Labs Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Laurus Labs Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 953.65, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 954.50 | 964.05 | 867.64 - 1,060.45 |
| 973.59 | 778.87 - 1,168.31 | ||
| 983.14 | 688.19 - 1,278.08 | ||
| Bearish Scenario | 954.50 | 944.96 | 850.46 - 1,039.45 |
| 935.41 | 748.33 - 1,122.49 | ||
| 925.87 | 648.11 - 1,203.62 |
Overview of Laurus Labs Limited
ISIN
INE947Q01028
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
1,994,704
Market Cap
524,304,933,154
Last Dividend
1.6
Official Website
IPO Date
2016-12-19
DCF Diff
997.72
DCF
-40
Financial Ratios Every Investor Needs
Stock Dividend of LAURUSLABS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-10-31 | October 31, 25 | 0.8 | 0.8 | 2025-10-31 | 2025-11-22 | |
| 2025-05-09 | May 09, 25 | 0.8 | 0.8 | 2025-05-09 | 2025-05-20 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 5,553.96 Cr | 2,588.71 Cr | 2,965.25 Cr | 0.5339 | 55.30 Cr | 723.08 Cr | 2,173.09 Cr | 358.32 Cr | 6.65 | 1,034.19 Cr | 0.0645 |
| 2024-03-31 | 5,040.83 Cr | 2,539.79 Cr | 2,501.04 Cr | 0.4962 | 43.76 Cr | 642.19 Cr | 1,804.41 Cr | 160.55 Cr | 2.98 | 762.86 Cr | 0.0318 |
| 2023-03-31 | 6,040.55 Cr | 2,859.78 Cr | 3,180.77 Cr | 0.5266 | 25.59 Cr | 582.94 Cr | 2,555.64 Cr | 790.11 Cr | 14.69 | 1,605.93 Cr | 0.1308 |
| 2022-03-31 | 4,935.57 Cr | 2,248.82 Cr | 2,686.75 Cr | 0.5444 | 29.47 Cr | 503.84 Cr | 2,152.95 Cr | 827.52 Cr | 15.42 | 1,417.71 Cr | 0.1677 |
| 2021-03-31 | 4,813.51 Cr | 2,199.03 Cr | 2,614.48 Cr | 0.5432 | 17.29 Cr | 436.12 Cr | 2,159.18 Cr | 983.58 Cr | 18.36 | 1,549.78 Cr | 0.2043 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 99.54 Cr | 9,335.57 Cr | 4,733.05 Cr | 4,472.5600 Cr | 2,763.73 Cr | 2,619.52 Cr | 1,936.54 Cr | 4,315.96 Cr | 47.59 Cr | 347.60 Cr | 233.26 Cr | 3,539.7200 Cr |
| 2024-03-31 | 138.94 Cr | 8,387.03 Cr | 4,271.46 Cr | 4,110.9500 Cr | 2,577.40 Cr | 2,438.46 Cr | 1,845.41 Cr | 4,047.53 Cr | 81.85 Cr | 105.95 Cr | 123.98 Cr | 3,112.2800 Cr |
| 2023-03-31 | 45.67 Cr | 7,660.40 Cr | 3,611.74 Cr | 4,037.5300 Cr | 2,015.09 Cr | 1,969.42 Cr | 1,684.81 Cr | 3,700.17 Cr | 277.42 Cr | 125.50 Cr | 49.90 Cr | 2,432.2600 Cr |
| 2022-03-31 | 75.35 Cr | 6,968.04 Cr | 3,608.99 Cr | 3,351.1900 Cr | 1,776.66 Cr | 1,701.31 Cr | 1,760.30 Cr | 3,208.56 Cr | 616.06 Cr | 67.03 Cr | 62.78 Cr | 2,681.0100 Cr |
| 2021-03-31 | 48.46 Cr | 5,750.69 Cr | 3,149.99 Cr | 2,597.5500 Cr | 1,481.69 Cr | 1,433.23 Cr | 1,575.45 Cr | 2,277.17 Cr | 222.68 Cr | 71.84 Cr | -35.35 Cr | 2,457.1500 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 601.6500 Cr | -681.7200 Cr | 39.2800 Cr | -39.3500 Cr | -39.4000 Cr | 99.5400 Cr | -641.0000 Cr | 358.3200 Cr | 187.0700 Cr | -43.1300 Cr | -82.8600 Cr |
| 2024-03-31 | 665.6900 Cr | -822.4200 Cr | 249.8300 Cr | -12.6200 Cr | 93.2700 Cr | 138.9400 Cr | -678.3100 Cr | 160.5500 Cr | 541.0500 Cr | -86.1800 Cr | -151.3100 Cr |
| 2023-03-31 | 993.9000 Cr | -996.0600 Cr | -26.6400 Cr | 3.7400 Cr | -29.6800 Cr | 45.6700 Cr | -990.1600 Cr | 1,108.9400 Cr | 221.6200 Cr | -107.4700 Cr | 81.8300 Cr |
| 2022-03-31 | 911.1000 Cr | -914.3400 Cr | 30.2600 Cr | 34.2600 Cr | 26.8900 Cr | 75.3500 Cr | -876.8400 Cr | 1,083.8500 Cr | 270.2400 Cr | -85.8600 Cr | -174.3300 Cr |
| 2021-03-31 | 733.0000 Cr | -940.9900 Cr | 254.7000 Cr | 44.2300 Cr | 46.7700 Cr | 48.4600 Cr | -688.7700 Cr | 1,301.1100 Cr | 391.0700 Cr | -75.0400 Cr | -660.1700 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 1,569.57 Cr | 637.35 Cr | 932.22 Cr | 0.5939 | 717.42 Cr | 163.02 Cr | 3.02 | 367.54 Cr | 0.1039 |
| 2025-03-31 | 1,720.30 Cr | 893.41 Cr | 826.89 Cr | 0.4807 | 576.55 Cr | 233.67 Cr | 4.34 | 412.42 Cr | 0.1358 |
| 2024-12-31 | 1,415.05 Cr | 610.15 Cr | 804.90 Cr | 0.5688 | 615.78 Cr | 92.30 Cr | 1.71 | 271.06 Cr | 0.0652 |
| 2024-09-30 | 1,223.70 Cr | 548.30 Cr | 675.40 Cr | 0.5519 | 496.68 Cr | 19.84 Cr | 0.37 | 177.61 Cr | 0.0162 |
| 2024-06-30 | 1,194.91 Cr | 536.85 Cr | 658.06 Cr | 0.5507 | 484.08 Cr | 12.51 Cr | 0.23 | 159.65 Cr | 0.0105 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 0.00 Cr | 0.00 Cr | 144.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,602.52 Cr |
| 2025-03-31 | 50.64 Cr | 0.00 Cr | 50.64 Cr | 2,040.92 Cr | 1,738.88 Cr | 4,006.78 Cr | 4,315.96 Cr | 9,335.57 Cr | 4,733.05 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 44.92 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -4,144.16 Cr |
| 2024-09-30 | 44.92 Cr | 8.65 Cr | 44.92 Cr | 1,750.76 Cr | 2,107.13 Cr | 4,119.71 Cr | 4,094.02 Cr | 8,729.28 Cr | 4,585.12 Cr |
| 2024-06-30 | -141.65 Cr | 283.30 Cr | 141.65 Cr | 0.00 Cr | 0.00 Cr | 141.65 Cr | 0.00 Cr | 0.00 Cr | -4,115.57 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | 163.02 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2025-03-31 | 233.67 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 92.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 19.84 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 12.51 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-29 | September 29, 20 | 5:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,690.70 | ₹4,056,549,508,373.00 | ₹1,560,907.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,738.00 | ₹1,788,732,898,056.00 | ₹507,645.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,560.10 | ₹1,204,898,044,500.00 | ₹354,021.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,197.60 | ₹996,839,216,220.00 | ₹4,250,056.00 |
| Mankind Pharma Limited | MANKIND | ₹2,384.00 | ₹984,016,240,160.00 | ₹593,366.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹974.45 | ₹980,520,395,716.00 | ₹458,971.00 |
| Lupin Limited | LUPIN | ₹1,963.50 | ₹896,844,333,000.00 | ₹1,017,447.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,138.90 | ₹661,474,968,435.00 | ₹3,556,831.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,506.50 | ₹658,384,672,500.00 | ₹178,327.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,891.20 | ₹533,698,169,981.00 | ₹398,054.00 |
| Laurus Labs Limited | LAURUSLABS | ₹953.65 | ₹514,804,014,931.00 | ₹1,545,364.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,271.20 | ₹322,508,801,922.00 | ₹106,442.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,465.30 | ₹308,003,793,847.00 | ₹102,941.00 |
| Cohance Lifesciences Limited | COHANCE | ₹753.40 | ₹288,226,083,276.00 | ₹1,868,840.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,682.30 | ₹263,441,852,870.00 | ₹161,890.00 |
| Piramal Enterprises Limited | PEL | ₹1,124.20 | ₹254,856,250,172.00 | ₹2,148,582.00 |
| Emcure Pharmaceuticals Ltd. | EMCURE | ₹1,318.90 | ₹250,017,076,708.00 | ₹201,166.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,555.00 | ₹238,875,000,000.00 | ₹20,033.00 |
| Eris Lifesciences Limited | ERIS | ₹1,591.70 | ₹216,811,113,902.00 | ₹40,393.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹16,473.00 | ₹211,346,761,497.00 | ₹44,604.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,281.50 | ₹208,224,272,482.00 | ₹289,135.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹897.40 | ₹176,395,747,478.00 | ₹69,233.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,101.00 | ₹174,564,413,184.00 | ₹543,954.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,032.80 | ₹154,516,575,629.00 | ₹43,860.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹819.90 | ₹146,852,182,413.00 | ₹412,467.00 |
| Granules India Limited | GRANULES | ₹565.60 | ₹137,253,425,770.00 | ₹384,397.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Alivus Life Sciences Ltd. | ALIVUS | ₹904.45 | ₹110,959,145,199.00 | ₹27,710.00 |
| Procter & Gamble Health Limited | PGHL | ₹6,152.00 | ₹102,119,398,064.00 | ₹17,413.00 |
| Strides Pharma Science Limited | STAR | ₹934.70 | ₹86,153,835,776.00 | ₹9,219,602.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹851.95 | ₹77,214,757,940.00 | ₹105,286.00 |
| FDC Limited | FDC | ₹460.65 | ₹74,998,465,195.00 | ₹252,540.00 |
| Akums Drugs & Pharmaceuticals Ltd. | AKUMS | ₹460.75 | ₹70,541,773,224.00 | ₹53,334.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹352.85 | ₹69,011,043,776.00 | ₹149,611.00 |
| Sequent Scientific Limited | SEQUENT | ₹214.61 | ₹53,633,796,524.00 | ₹1,034,635.00 |
| Gujarat Themis Biosyn Ltd. | GUJTHEM | ₹465.10 | ₹50,679,744,752.00 | ₹51,856.00 |
| Innova Captab Limited | INNOVACAP | ₹831.10 | ₹47,559,638,492.00 | ₹13,222.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹491.10 | ₹44,822,697,000.00 | ₹54,690.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹135.19 | ₹43,872,073,482.00 | ₹196,488.00 |
| Suven Life Sciences Limited | SUVEN | ₹197.55 | ₹43,073,939,692.00 | ₹121,404.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,403.90 | ₹39,758,138,159.00 | ₹6,281.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹726.30 | ₹36,837,285,962.00 | ₹86,074.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹470.95 | ₹33,157,587,963.00 | ₹3,282.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹325.40 | ₹32,631,927,452.00 | ₹54,623.00 |
Key Executives
Chief Financial Officer & Whole-Time Director
Mr. Vantaram Venkata Ravi Kumar Dip in Mgmt., DIS, F.C.M.A.
Gender: male
Year Born: 1965
Executive Vice President of Manufacturing
Mr. Srinivasa Rao Suryadevara B.Sc, M.Sc.
Gender: male
Year Born: 1963
Chief Executive Officer & Whole Time Director
Dr. Satyanarayana Chava M.Sc., Ph.D.
Gender: Not Specified
Year Born: 1961
Executive Vice President of Manufacturing & Operations
Mr. B. V. R. K. Suryadevara Srinivasa Rao
Gender: male
Year Born: 1968
Executive Vice President of Human Resources
Mr. Narasimha Rao Chava
Gender: male
Year Born: 1968
Head of Quality & Executive Director
Dr. Lakshmana Rao Venkata Chunduru M.Sc., Ph.D.
Gender: Not Specified
Year Born: 1962
Executive Vice President of Finance
Mr. Chagarlamudi Sita Ramaiah
Gender: male
Year Born: 1973
Executive Vice President of Synthesis
Mr. Dammalapati Venkata Lakshmi Narasimha Rao
Gender: male
Year Born: 1969
Executive Vice President, Head of Synthesis & Ingredients and Executive Director
Mr. Krishna Chaitanya Chava
Gender: male
Year Born: 1990
Executive Vice President of Portfolio Management
Mr. Rajaram Iyer M.B.A.
Gender: male
Year Born: 1974
FAQs about Laurus Labs Limited
Who is the CEO of the company?
The CEO is Satyanarayana Chava.
What is the current market price of the stock?
The current price is ₹971.25.
What is the 52-week price range?
The range is ₹474.05-971.8.
What is the market capitalization of the company?
The market capitalization is ₹52,430.49 crores.
What is the dividend yield?
The dividend yield is 0.08%.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 103.04.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Laurus Labs Limited (ISIN: INE947Q01028) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹52,430.49 crores and an average daily volume of 1,994,704 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹1.6.